Uterine Fibroids (Leiomyomas)
Also known as: Leiomyomas / Leiomyoma / Fibroid / Fibroids / Leiomyoma, Uterine / Uterine Leiomyoma / Uterine Leiomyomas / Uterine Myoma / Uterine Myomas / Fibroids, Uterine / Uterine Fibroids / Uterine Fibroid / [M]Leiomyoma NOS (morphologic abnormality) / [M]Leiomyomatous neoplasm NOS (morphologic abnormality) / [M]Leiomyomatous neoplasms (morphologic abnormality) / Leiomyoma NOS / Leiomyofibroma (morphologic abnormality) / Uterine fibroma / Fibroid Uterus / Uterine leiomyoma (disorder) / Leiomyoma of uterus, unspecified / Uterine fibromyoma / Leiomyoma of uterus / Leiomyoma, no ICD-O subtype (morphologic abnormality) / Uterine leiomyoma NOS (disorder) / Leiomyoma (disorder)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB11979 | Elagolix | A gonadotropin releasing hormone receptor antagonist used to treat moderate to severe pain in endometriosis. |
| DB00783 | Estradiol | An estrogenic steroid used to treat vasomotor symptoms of vulvar and vaginal atrophy in menopause, hypoestrogenism, prevention of postmenopausal osteoporosis, treatment of breast cancer, and advanced androgen-dependent carcinoma of the prostate. |
| DB00007 | Leuprolide | A peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty. |
| DB00717 | Norethisterone | A synthetic second-generation progestin used for contraception, prevention of endometrial hyperplasia in hormone replacement therapy, and in the treatment of other hormone-mediated illnesses such as endometriosis. |
| DB11853 | Relugolix | An oral GnRH receptor antagonist for androgen deprivation therapy in the treatment of advanced prostate cancer. |